Recently, the incidence of myopia has been rising year by year among adolescents with a trend toward younger children. At present, some methods used in treating and controlling myopia are eyeglass spectacles, orthokeratology lenses, drugs, etc. Among these methods, the effect of atropine in high concentrations (1%, 0.5% and 0.1%) can effectively reduce the refractive error and axial length elongation of myopia. However, there are some side effects from its pharmacological activity, such as photophobia and near vision blur, etc. But these side effects are not present in low concentrations (0.01%). This paper presents a simple summary of the use of atropine for the cure and control of myopia.
贺美男,魏瑞华. 阿托品控制近视增长的研究进展[J]. 中华眼视光学与视觉科学杂志, 2016, 18(10): 632-635.
He Meinan,Wei Ruihua. A review of atropine for the treatment of myopia. Chinese Journal of Optometry Ophthalmology and Visual science, 2016, 18(10): 632-635. DOI: DOI:10.3760/cma.j.issn.1674-845X.2016.10.013
Pan CW, Ramamurthy D, Saw SM. Worldwide prevalence and risk factors for myopia[J]. Ophthalmic Physiol Opt,2012,32(1): 3-16. DOI:10.1111/j.1475-1313.2011.00884.x.
[2]
Charman N. Myopia: its prevalence, origins and control[J]. Ophthalmic Physiol Opt,2011,31(1):3-6. DOI:10.1111/j.1475-1313. 2010.00808.x.
[3]
Leo SW, Young TL. An evidence-based update on myopia and interventions to retard its progression[J]. J AAPOS,2011,15(2): 181-189. DOI:10.1016/j.jaapos.2010.09.020.
[4]
Polling JR, Kok RG, Tideman JW, et al. Effectiveness study of atropine for progressive myopia in Europeans[J]. Eye (Lond),2016, 30(7):998-1004. DOI:10.1038/eye.2016.78.
[5]
Recko M, Stahl ED. Childhood myopia: epidemiology, risk factors, and prevention[J]. Mo Med,2015,112(2):116-121.
[6]
Walline JJ, Lindsley K, Vedula SS, et al. Interventions to slow progression of myopia in children[J]. Cochrane Database Syst Rev,2011(12): CD004916. DOI:10.1002/14651858.CD004916.pub3.
[7]
Chassine T, Villain M, Hamel CP, et al. How can we prevent myopia progression?[J]. Eur J Ophthalmol,2015,25(4):280-285.DOI:10.5301/ejo.5000571.
[8]
Huang J, Wen D, Wang Q, et al. Efficacy comparison of 16 interventions for myopia control in children: A network meta-analysis[J]. Ophthalmology,2016,123(4):697-708. DOI:10.1016/j.ophtha.2015.11.010.
[9]
Yi S, Huang Y, Yu SZ, et al. Therapeutic effect of atropine 1% in children with low myopia[J]. J AAPOS,2015,19(5):426-429. DOI:10.1016/j.jaapos.2015.04.006.
[10]
Nishiyama Y, Moriyama M, Fukamachi M, et al. Side effects of low dose atropine[J]. Nippon Ganka Gakkai Zasshi,2015,119(11): 812-816.
[11]
Galvis V, Tello A, Parra MM, et al. Re: Chia et al.: Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops (Ophthalmology 2016;123:391-9)[J]. Ophthalmology,2016,123(6):e40-41. DOI:10.1016/j.ophtha.2015.12.037.
[12]
Gimbel HV. The control of myopia with atropine[J]. Can J Ophthalmol,1973,8(4):527-532.
[13]
Li SM, Wu SS, Kang MT, et al. Atropine slows myopia progression more in Asian than white children by meta-analysis[J]. Optom Vis Sci,2014,91(3):342-350. DOI:10.1097/OPX.0000000000000178.
[14]
Shih KC, Chan TC, Ng AL, et al. Use of atropine for prevention of childhood myopia progression in clinical practice[J]. Eye Contact Lens,2016,42(1):16-23. DOI:10.1097/ICL.0000000000000189.
[15]
Grzybowski A, Armesto A, Szwajkowska M, et al. The role of atropine eye drops in myopia control[J]. Curr Pharm Des,2015,21(32):4718-4730.
Wu PC, Yang YH, Fang PC. The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren[J]. J Ocul Pharmacol Ther,2011,27(5):461-466. DOI:10.1089/jop.2011.0027.
[18]
Shih YF, Chen CH, Chou AC, et al. Effects of different concentrations of atropine on controlling myopia in myopic children[J]. J Ocul Pharmacol Ther,1999,15(1):85-90. DOI:10. 1089/jop.1999.15.85.
[19]
Shih YF, Hsiao CK, Chen CJ, et al. An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression[J]. Acta Ophthalmol Scand,2001,79(3):233-236.
[20]
Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of childhood myopia[J]. Ophthalmology,2006,113(12): 2285-2291. DOI:10.1016/j.ophtha.2006.05.062.
[21]
Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2)[J]. Ophthalmology,2012,119(2):347-354. DOI:10.1016/j.ophtha.2011. 07.031.
[22]
Lin L, Lan W, Liao Y, et al. Treatment outcomes of myopic anisometropia with 1% atropine: A pilot study[J]. Optom Vis Sci,2013,90(12):1486-1492.DOI:10.1097/OPX.0000000000000097.
[23]
Loh KL, Lu Q, Tan D, et al. Risk factors for progressive myopia in the atropine therapy for myopia study[J]. Am J Ophthalmol, 2015,159(5):945-949. DOI:10.1016/j.ajo.2015.01.029.
Sato T. The cause and prevention of school myopia. Amsterdam: Excerpta Mediea,1993,12(02):28-58.
[26]
McBrien NA, Stell WK, Carr B. How does atropine exert its anti-myopia effects?[J]. Ophthalmic Physiol Opt,2013,33(3):373-378. DOI:10.1111/opo.12052.
[27]
Stone RA, Pardue MT, Iuvone PM, et al. Pharmacology of myopia and potential role for intrinsic retinal circadian rhythms[J]. Exp Eye Res,2013,114: 35-47. DOI:10.1016/j.exer.2013.01.001.
[28]
Gallego P, Martinez-Garcia C, Perez-Merino P, et al. Scleral changes induced by atropine in chicks as an experimental model of myopia[J]. Ophthalmic Physiol Opt,2012,32(6):478-484. DOI: 10.1111/j.1475-1313.2012.00940.x.
[29]
Barathi VA, Beuerman RW. Molecular mechanisms of muscarinic receptors in mouse scleral fibroblasts: Prior to and after induction of experimental myopia with atropine treatment[J]. Mol Vis,2011, 17:680-692.
[30]
Arumugam B, McBrien NA. Muscarinic antagonist control of myopia: evidence for M4 and M1 receptor-based pathways in the inhibition of experimentally-induced axial myopia in the tree shrew[J]. Invest Ophthalmol Vis Sci,2012,53(9):5827-5837. DOI: 10.1167/iovs.12-9943.
[31]
Loughman J, Flitcroft DI. The acceptability and visual impact of 0.01% atropine in a Caucasian population[J]. Br J Ophthalmol,2016. DOI:10.1136/bjophthalmol-2015-307861.
[32]
Chia A, Lu QS, Tan D. Five-year clinical trial on atropine for the treatment of myopia 2: Myopia control with atropine 0.01% eyedrops[J]. Ophthalmology,2016,123(2):391-399. DOI:10.1016/j.ophtha.2015.07.004.
[33]
Cooper J, Eisenberg N, Schulman E, et al. Maximum atropine dose without clinical signs or symptoms[J]. Optom Vis Sci,2013, 90(12):1467-1472.
[34]
Tong L, Huang XL, Koh AL, et al. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine[J]. Ophthalmology,2009,116(3):572-579. DOI:10.1016/j.ophtha.2008.10.020.
[35]
Wu TE, Yang CC, Chen HS. Does atropine use increase intraocular pressure in myopic children?[J]. Optom Vis Sci,2012, 89(2):E161-167. DOI:10.1097/OPX.0b013e31823ac4c1.
Chia A, Li W, Tan D, et al. Full-field electroretinogram findings in children in the atropine treatment for myopia (ATOM2) study[J]. Doc Ophthalmol,2013,126(3):177-186. DOI:10.1007/s10633-012-9372-8.